INSTITUT CLAUDIUS REGAUD

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.claudiusregaud.fr

Clinical Trials

Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)

Phase 1

Withdrawn

Conditions: Prostatic Cancer, Castration-Resistant

Interventions: Drug: SXL01

First Posted Date: 2016-08-15

Last Posted Date: 2021-01-20

Lead Sponsor: Institut Claudius Regaud

Registration Number: NCT02866916

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France

From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers

Not Applicable

Conditions: Breast Cancer

Interventions: Other: cohort of BC of each subtypes

First Posted Date: 2016-08-11

Last Posted Date: 2016-08-11

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 350

Registration Number: NCT02863900

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France

Evaluation of an Organized Consultation "Return Home" of Patients With a Cancer (CREDO)

Not Applicable

Completed

Conditions: METASTATIC CANCER

Interventions: Other: current standard of care
Other: CREDO standard of care

First Posted Date: 2016-08-05

Last Posted Date: 2022-09-29

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 667

Registration Number: NCT02857400

Locations: 🇫🇷
Centre Hospitalier Auch, Auch, France
🇫🇷
Hopital Rangueil, Toulouse, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

Not Applicable

Completed

Conditions: Medullary Thyroid Cancer

Interventions: Other: 18F-DOPA

First Posted Date: 2016-08-04

Last Posted Date: 2021-03-08

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 24

Registration Number: NCT02856347

Locations: 🇫🇷
CHU Haut-Lévêque, Bordeaux, France
🇫🇷
CHU Limoges, Limoges, France
🇫🇷
CHU Timone, Marseille, France

and more 2 locations

Cost Utility of Radical Surgery in Ovarian Cancer

Not Applicable

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Other: Collection of additional data with questionnaires

First Posted Date: 2016-08-03

Last Posted Date: 2024-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 200

Registration Number: NCT02854215

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷
Chu Clermont Ferrand, Clermont Ferrand, France

and more 7 locations

Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment

Not Applicable

Completed

Conditions: Solid Tumors

Interventions: Other: Telephone follow-up nursing device

First Posted Date: 2015-12-02

Last Posted Date: 2018-03-02

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 200

Registration Number: NCT02619045

Locations: 🇫🇷
Institut claudius regaud, Toulouse, France

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Metastatic Renal Cell Cancer

Interventions: Drug: Sunitinib
Drug: Pazopanib

First Posted Date: 2015-09-22

Last Posted Date: 2021-01-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 47

Registration Number: NCT02555748

Locations: 🇫🇷
CHU DE BORDEAUX - Hôpital Saint-André, Bordeaux, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
CHU DE LIMOGES - Hôpital Dupuytren, Limoges, France

and more 5 locations

Therapeutic Nipple Sparing Mastectomy.

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Procedure: Nipple sparing mastectomy

First Posted Date: 2014-12-09

Last Posted Date: 2024-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 450

Registration Number: NCT02311959

Locations: 🇫🇷
Hôpital privé Drôme Ardèche, Guilherand-Granges, France
🇫🇷
Clinique du Mail, La Rochelle, France
🇫🇷
Pôle santé Léonard de Vinci, Chambray-lès-Tours, France

and more 30 locations

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

Not Applicable

Completed

Conditions: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm

Interventions: Procedure: Blood samples of 10 mL

First Posted Date: 2014-10-17

Last Posted Date: 2024-12-03

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 151

Registration Number: NCT02266420

Locations: 🇫🇷
Institut Regional Du Cancer Montpellier, Montpellier, France
🇫🇷
CH Emile ROUX, Le Puy-en-Velay, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 8 locations

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Phase 2

Completed

Conditions: Advanced Urothelial Cancer
Metastatic Urothelial Cancer

Interventions: Drug: Fractionated Cisplatin
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2014-09-15

Last Posted Date: 2019-08-09

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 46

Registration Number: NCT02240017

Locations: 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷
INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Paul Papin, Angers, France
🇫🇷
Chru Besancon - Hopital Jean Minjoz, Besançon, France

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy